Sentence examples for making this receptor from inspiring English sources

Erb-B family receptor elevations are found in many non-small cell lung cancer tumors, making this receptor family a drug target with potential for improving survival.

Disruption of molecular interactions between the hVDR and its natural ligand result in adverse diseases, such as rickets, making this receptor a good target for drug discovery.

Gain-of-function mutations in NOTCH1 are common in T-cell lymphoblastic leukemias and lymphomas (T-ALL), making this receptor a promising target for drugs such as gamma-secretase inhibitors, which block a proteolytic cleavage required for NOTCH1 activation.

B2AR is also one of the most studied 7TM structures; it was first crystalized in 2007 [8], and as of November 2014, 16 crystals with a variety of structurally and functionally unique ligands are available via the Protein Data Bank (PDB), making this receptor a strong base for in silico structural studies.

When these drugs bind to TLR4 their addictiveness is amplified, making this receptor a potential target for opioid and cocaine addiction treatments.

This receptor is also the route by which HIV-1 infection occurs, making this receptor a therapeutic target in AIDS treatment [ 11].

For aP2, the ability of the receptor protein to change its hydrogen bond interactions in the β-strands to accommodate different ligand scaffolds seems to make this receptor difficult for structure based drug design.

It is interesting that LDLR and LRP1 have overlapping binding properties for apoE3 and apoE4; however, LRP1's high expression level in the brain and fast endocytosis rate likely make this receptor an important candidate for Aβ metabolism in the brain.

Indeed, certain tumor cells are dependent on EGFR signaling and thus possess an "Oncogene addiction", which makes this receptor an attractive target for therapy [7].

However, the fact that specific A2A agonists are currently being tested in clinical trials for other diseases makes this receptor an attractive target for therapeutic advancement in human ALI/ARDS.

However, these authors found that the structure-activity relationship, characterized by the preference for alkyl over acyl LPA analogues, is similar to that of LPA5, which makes this receptor a candidate for the activating LPA receptor subtype in platelets (Williams et al., 2009).